

Egesta Lopci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2266052/publications.pdf>

Version: 2024-02-01

161
papers

3,939
citations

147801

31
h-index

155660

55
g-index

167
all docs

167
docs citations

167
times ranked

5760
citing authors

#	ARTICLE	IF	CITATIONS
1	Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 540-557.	6.4	348
2	High-dimensional single cell analysis identifies stem-like cytotoxic CD8+ T cells infiltrating human tumors. <i>Journal of Experimental Medicine</i> , 2018, 215, 2520-2535.	8.5	250
3	FDG PET/CT for assessing tumour response to immunotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 238-250.	6.4	194
4	Diagnostic accuracy and impact on management of 18F-FDG PET and PET/CT in colorectal liver metastasis: a meta-analysis and systematic review. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 152-163.	6.4	124
5	Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1954-1961.	6.4	122
6	Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 57-71.	6.4	111
7	PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 4, 365-84.	1.0	109
8	IRF4 instructs effector Treg differentiation and immune suppression in human cancer. <i>Journal of Clinical Investigation</i> , 2020, 130, 3137-3150.	8.2	103
9	Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group. <i>Lancet Oncology</i> , 2018, 19, e534-e545.	10.7	98
10	Guidelines on nuclear medicine imaging in neuroblastoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2009-2024.	6.4	94
11	⁶⁸ Ga-PSMA Positron Emission Tomography/Computerized Tomography for Primary Diagnosis of Prostate Cancer in Men with Contraindications to or Negative Multiparametric Magnetic Resonance Imaging: A Prospective Observational Study. <i>Journal of Urology</i> , 2018, 200, 95-103.	0.4	85
12	Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1155-1164.	6.4	76
13	Hyperprogressive Disease in Patients with Non-Small Cell Lung Cancer Treated with Checkpoint Inhibitors: The Role of ¹⁸ F-FDG PET/CT. <i>Journal of Nuclear Medicine</i> , 2020, 61, 821-826.	5.0	73
14	The role of Fluorine-18-Fluorodeoxyglucose positron emission tomography in staging and restaging of patients with osteosarcoma. <i>Radiology and Oncology</i> , 2013, 47, 97-183.	1.7	69
15	18F-DOPA PET/CT in Neuroblastoma. <i>Clinical Nuclear Medicine</i> , 2012, 37, e73-e78.	1.3	63
16	⁶⁴ CuCl ₂ PET/CT in Prostate Cancer Relapse. <i>Journal of Nuclear Medicine</i> , 2018, 59, 444-451.	5.0	57
17	The role of ¹⁸ F-FDG PET/CT in the metabolic characterization of lung nodules in pediatric patients with bone sarcoma. <i>Pediatric Blood and Cancer</i> , 2012, 59, 1206-1210.	1.5	55
18	Incorporating radiomics into clinical trials: expert consensus endorsed by the European Society of Radiology on considerations for data-driven compared to biologically driven quantitative biomarkers. <i>European Radiology</i> , 2021, 31, 6001-6012.	4.5	53

#	ARTICLE	IF	CITATIONS
19	Salvage therapy of intraprostatic failure after radical external-beam radiotherapy for prostate cancer: A review. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, 550-563.	4.4	52
20	Prognostic value of 18F-DOPA PET/CT at the time of recurrence in patients affected by neuroblastoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1046-1056.	6.4	49
21	Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2323-2341.	6.4	48
22	Is it time to change our vision of tumor metabolism prior to immunotherapy?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1072-1075.	6.4	47
23	Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 2310-2325.	6.4	46
24	Comparison Between ¹⁸ F-FDG PET-Based and CT-Based Criteria in Non-Small Cell Lung Cancer Patients Treated with Nivolumab. <i>Journal of Nuclear Medicine</i> , 2020, 61, 990-998.	5.0	44
25	Investigation on the role of integrated PET/MRI for target volume definition and radiotherapy planning in patients with high grade glioma. <i>Radiotherapy and Oncology</i> , 2014, 112, 425-429.	0.6	42
26	Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 667-675.	6.4	42
27	Matched pairs dosimetry: 124I/131I metaiodobenzylguanidine and 124I/131I and 86Y/90Y antibodies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 28-40.	6.4	39
28	The immune-metabolic-prognostic index and clinical outcomes in patients with non-small cell lung carcinoma under checkpoint inhibitors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1235-1243.	2.5	39
29	MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients. <i>Annals of Oncology</i> , 2010, 21, 1173-1178.	1.2	38
30	Usefulness of 64Cu-ATSM in Head and Neck Cancer. <i>Clinical Nuclear Medicine</i> , 2014, 39, e59-e63.	1.3	36
31	Prostate-specific antigen flare induced by 223RaCl ₂ in patients with metastatic castration-resistant prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2256-2263.	6.4	36
32	Diagnostic accuracy of 11C-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1399-1407.	6.4	33
33	Diagnosis, Treatment Response, and Prognosis: The Role of ¹⁸ F-DOPA PET/CT in Children Affected by Neuroblastoma in Comparison with ¹²³ I-mIBG Scan: The First Prospective Study. <i>Journal of Nuclear Medicine</i> , 2020, 61, 367-374.	5.0	33
34	FDG PET/CT predictive role in follicular lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 864-871.	6.4	32
35	Prognostic Evaluation of Disease Outcome in Solid Tumors Investigated With 64Cu-ATSM PET/CT. <i>Clinical Nuclear Medicine</i> , 2016, 41, e87-e92.	1.3	32
36	Prospective Evaluation of 68Ga-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography in Primary Prostate Cancer Diagnosis. <i>European Urology Focus</i> , 2021, 7, 764-771.	3.1	32

#	ARTICLE	IF	CITATIONS
37	¹⁸ F-FDG PET in Pediatric Lymphomas: A Comparison with Conventional Imaging. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2008, 23, 681-690.	1.0	29
38	Epstein-Barr virus BART microRNAs in EBV- associated Hodgkin lymphoma and gastric cancer. <i>Infectious Agents and Cancer</i> , 2020, 15, 42.	2.6	29
39	Circulating Tumor Cells and Metabolic Parameters in NSCLC Patients Treated with Checkpoint Inhibitors. <i>Cancers</i> , 2020, 12, 487.	3.7	29
40	¹⁸ F-FDG PET/CT for response assessment in Hodgkin lymphoma undergoing immunotherapy with checkpoint inhibitors. <i>Leukemia and Lymphoma</i> , 2019, 60, 367-375.	1.3	27
41	FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study. <i>Annals of Oncology</i> , 2010, 21, 1877-1883.	1.2	26
42	Ability of 18F-DOPA PET/CT and fused 18F-DOPA PET/MRI to assess striatal involvement in paediatric glioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1664-1672.	6.4	25
43	Frameless stereotactic biopsy for precision neurosurgery: diagnostic value, safety, and accuracy. <i>Acta Neurochirurgica</i> , 2019, 161, 967-974.	1.7	24
44	Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors and Its Correlation with Metabolic Parameters. <i>Cancers</i> , 2020, 12, 1373.	3.7	24
45	Imaging biomarkers in primary brain tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 597-612.	6.4	23
46	PET/CT imaging in neuroblastoma. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 57, 29-39.	0.7	23
47	Prognostic and predictive role of [¹⁸ F]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy. <i>Cancer Medicine</i> , 2017, 6, 2287-2296.	2.8	22
48	Report of the 6th International Workshop on PET in lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 2298-2303.	1.3	21
49	Impact of Antibiotic Therapy and Metabolic Parameters in Non-Small Cell Lung Cancer Patients Receiving Checkpoint Inhibitors. <i>Journal of Clinical Medicine</i> , 2021, 10, 1251.	2.4	21
50	[11C]Choline PET/CT Impacts Treatment Decision Making in Patients With Prostate Cancer Referred for Radiotherapy. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 155-159.	1.9	20
51	Immunotherapy in non-small-cell lung cancer: potential predictors of response and new strategies to assess activity. <i>Immunotherapy</i> , 2018, 10, 797-805.	2.0	20
52	Metabolism of Stem and Progenitor Cells: Proper Methods to Answer Specific Questions. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 151.	2.9	20
53	Comparison of Metabolic and Morphological Response Criteria for Early Prediction of Response and Survival in NSCLC Patients Treated With Anti-PD-1/PD-L1. <i>Frontiers in Oncology</i> , 2020, 10, 1090.	2.8	20
54	Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [18F]FDG PET/CT in Metastatic Melanomas and Lung Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 5160.	2.4	20

#	ARTICLE	IF	CITATIONS
55	Bone and Lymph Node Metastases From Neuroblastoma Detected by 18F-DOPA-PET/CT and Confirmed by Posttherapy 131I-MIBG but Negative on Diagnostic 123I-MIBG Scan. <i>Clinical Nuclear Medicine</i> , 2014, 39, e80-e83.	1.3	18
56	Positron Emission Tomography-Computed Tomography for Patients with Recurrent Colorectal Liver Metastases: Impact on Restaging and Treatment Planning. <i>Annals of Surgical Oncology</i> , 2017, 24, 1029-1036.	1.5	17
57	18F-FDG PET/CT in Restaging and Evaluation of Response to Therapy in Lung Cancer: State of the Art. <i>Current Radiopharmaceuticals</i> , 2020, 13, 228-237.	0.8	17
58	The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab. <i>Cancers</i> , 2021, 13, 3117.	3.7	17
59	Positron-emission tomography in gynaecologic malignancies. <i>Archives of Gynecology and Obstetrics</i> , 2009, 280, 521-528.	1.7	16
60	Clinical staging of malignant pleural mesothelioma: current perspectives. <i>Lung Cancer: Targets and Therapy</i> , 2017, Volume 8, 127-139.	2.7	16
61	PSMA-PET and micro-ultrasound potential in the diagnostic pathway of prostate cancer. <i>Clinical and Translational Oncology</i> , 2021, 23, 172-178.	2.4	16
62	Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study. <i>Oncotarget</i> , 2017, 8, 67696-67708.	1.8	16
63	Postchemotherapy PET evaluation correlates with patient outcome in paediatric Hodgkin's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1620-1627.	6.4	15
64	Italian Multicenter Study on Accuracy of 18 F-FDG PET/CT in Assessing Bone Marrow Involvement in Pediatric Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e267-e273.	0.4	15
65	The Role of Radiomics in the Era of Immune Checkpoint Inhibitors: A New Protagonist in the Jungle of Response Criteria. <i>Journal of Clinical Medicine</i> , 2022, 11, 1740.	2.4	15
66	11C-Choline-Pet Guided Stereotactic Body Radiation Therapy for Lymph Node Metastases in Oligometastatic Prostate Cancer. <i>Cancer Investigation</i> , 2017, 35, 586-593.	1.3	14
67	Tumor heterogeneity, hypoxia, and immune markers in surgically resected non-small-cell lung cancer. <i>Nuclear Medicine Communications</i> , 2018, 39, 636-644.	1.1	14
68	The Complexity and Fractal Geometry of Nuclear Medicine Images. <i>Molecular Imaging and Biology</i> , 2019, 21, 401-409.	2.6	14
69	Evaluating response to immunotherapy with 18F-FDG PET/CT: where do we stand?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1019-1021.	6.4	14
70	Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography. <i>Frontiers in Oncology</i> , 2021, 11, 772530.	2.8	14
71	Joint EANM/SIOPE/RAPNO practice guidelines/SNMMI procedure standards for imaging of paediatric gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3852-3869.	6.4	14
72	Imaging with non-FDG PET tracers: outlook for current clinical applications. <i>Insights Into Imaging</i> , 2010, 1, 373-385.	3.4	13

#	ARTICLE	IF	CITATIONS
73	18F-DOPA PET/CT for assessment of response to induction chemotherapy in a child with high-risk neuroblastoma. <i>Pediatric Radiology</i> , 2014, 44, 355-361.	2.0	13
74	Feasibility of Carbidopa Premedication in Pediatric Patients: A Pilot Study. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2012, 27, 729-733.	1.0	11
75	What is the role of [11C]choline PET/CT in decision making strategy before post-operative salvage radiation therapy in prostate cancer patients?. <i>Acta Oncologica</i> , 2014, 53, 990-992.	1.8	11
76	Refining the management of patients with hepatocellular carcinoma integrating 11C-choline PET/CT scan into the multidisciplinary team discussion. <i>Nuclear Medicine Communications</i> , 2017, 38, 826-836.	1.1	11
77	Current Evidence on PET Response Assessment to Immunotherapy in Lymphomas. <i>PET Clinics</i> , 2020, 15, 23-34.	3.0	11
78	Impact of the COVID-19 crisis on imaging in oncological trials. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2054-2058.	6.4	11
79	Photopenic Defects in Gliomas With Amino-Acid PET and Relative Prognostic Value. <i>Clinical Nuclear Medicine</i> , 2021, 46, e36-e37.	1.3	11
80	68Ga Prostate-specific Membrane Antigen PET/CT for Primary Diagnosis of Prostate Cancer: Complementary or Alternative to Multiparametric MR Imaging. <i>Radiology</i> , 2018, 287, 725-726.	7.3	10
81	Incidental identification of osteoid osteoma by 68Ga-PSMA PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 509-510.	6.4	10
82	Independent expression of circulating and tissue levels of PD-L1: correlation of clusters with tumor metabolism and outcome in patients with non-small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1537-1545.	4.2	10
83	Lower Grade Gliomas: Relationships Between Metabolic and Structural Imaging with Grading and Molecular Factors. <i>World Neurosurgery</i> , 2019, 126, e270-e280.	1.3	10
84	Twenty Years On: RECIST as a Biomarker of Response in Solid Tumours an EORTC Imaging Group & ESOI Joint Paper. <i>Frontiers in Oncology</i> , 2021, 11, 800547.	2.8	10
85	SPECT- and PET-Based Patient-Tailored Treatment in Neuroendocrine Tumors. <i>Clinical Nuclear Medicine</i> , 2015, 40, e271-e277.	1.3	9
86	Targeted 11C-choline PET-CT/TRUS software fusion-guided prostate biopsy in men with persistently elevated PSA and negative mpMRI after previous negative biopsy. <i>European Journal of Hybrid Imaging</i> , 2017, 1, 9.	1.5	9
87	FDG PET in response evaluation of bulky masses in paediatric Hodgkin's lymphoma (HL) patients enrolled in the Italian AIEOP-LH2004 trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 97-106.	6.4	9
88	FDG-PET/CT Variants and Pitfalls in Haematological Malignancies. <i>Seminars in Nuclear Medicine</i> , 2021, 51, 554-571.	4.6	9
89	Non-FDG PET/CT. <i>Recent Results in Cancer Research</i> , 2020, 216, 669-718.	1.8	9
90	Clinical significance of axillary findings in patients with lymphoma during follow-up with 18F-fluorodeoxyglucose-PET. <i>Nuclear Medicine Communications</i> , 2008, 29, 705-710.	1.1	8

#	ARTICLE	IF	CITATIONS
91	Early and delayed evaluation of solid tumours with ⁶⁴ Cu-ATSM PET/CT. Nuclear Medicine Communications, 2017, 38, 340-346.	1.1	8
92	Role of ¹¹ C-choline PET/CT in radiation therapy planning of patients with prostate cancer. Nuclear Medicine Communications, 2018, 39, 951-956.	1.1	8
93	Deauville score: the Phoenix rising from ashes. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1043-1045.	6.4	8
94	“PET/CT Variants and Pitfalls in Lung Cancer and Mesothelioma” Seminars in Nuclear Medicine, 2021, 51, 458-473.	4.6	8
95	Update on tumor metabolism and patterns of response to immunotherapy. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 175-185.	0.7	8
96	¹¹ C Choline PET Guided Salvage Radiotherapy with Volumetric Modulation Arc Therapy and Hypofractionation for Recurrent Prostate Cancer after HIFU Failure: Preliminary Results of Tolerability and Acute Toxicity. TCRT Express, 2013, 13, 395-401.	1.5	7
97	Potential role of ¹⁸ F-DOPA PET in neuroblastoma. Clinical and Translational Imaging, 2016, 4, 79-86.	2.1	7
98	Prognostic Impact of Intratumoral Heterogeneity Based on Fractal Geometry Analysis in Operated NSCLC Patients. Molecular Imaging and Biology, 2019, 21, 965-972.	2.6	7
99	Advancing Imaging to Enhance Surgery. Neurosurgery Clinics of North America, 2021, 32, 31-46.	1.7	7
100	Impact of ¹¹ C-methionine positron emission tomography/computed tomography on radiation therapy planning and prognosis in patients with primary brain tumors. Tumori, 2014, 100, 636-644.	1.1	7
101	Impact of ¹¹ C-methionine positron emission tomography/computed tomography on radiation therapy planning and prognosis in patients with primary brain tumors. Tumori, 2014, 100, 636-44.	1.1	7
102	Response assessment of bone metastatic disease: seeing the forest for the trees RECIST, PERCIST, iRECIST, and PCWG-2. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 150-158.	0.7	7
103	Molecular Imaging in Oncology. Recent Results in Cancer Research, 2013, 187, 371-400.	1.8	6
104	Cardiac and Acoustic Metastases in Relapsing Melanoma. Clinical Nuclear Medicine, 2013, 38, e85-e88.	1.3	6
105	Cerebral Proliferative Angiopathy (CPA). Clinical Nuclear Medicine, 2016, 41, e527-e529.	1.3	6
106	Siewert type I and II oesophageal adenocarcinoma: sensitivity/specificity of computed tomography, positron emission tomography and endoscopic ultrasound for assessment of lymph node metastases in groups of thoracic and abdominal lymph node stations. Interactive Cardiovascular and Thoracic Surgery, 2019, 28, 518-525.	1.1	6
107	The Role of PET/CT in the Era of Immune Checkpoint Inhibitors: State of Art. Current Radiopharmaceuticals, 2020, 13, 24-31.	0.8	6
108	Gallium-68 DOTANOC imaging in paraganglioma/pheochromocytoma: presentation of sample cases and review of the literature. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2013, 57, 134-45.	0.7	6

#	ARTICLE	IF	CITATIONS
109	Imaging acute spinal myelitis with 18F-FDG PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 399-400.	6.4	5
110	11C-Methionine uptake in secondary brain epilepsy. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2014, 33, 234-236.	0.0	5
111	Re: Laura Evangelista, Alberto Briganti, Stefano Fanti, et al. New Clinical Indications for 18F/11C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. <i>Eur Urol</i> 2016;70:161-75. <i>European Urology</i> , 2016, 70, e112-e113.	1.9	5
112	Diffusion-weighted imaging and loco-regional N staging of patients with colorectal liver metastases. <i>European Journal of Surgical Oncology</i> , 2019, 45, 347-352.	1.0	5
113	Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy. <i>Clinical Lung Cancer</i> , 2020, 21, 28-36.	2.6	5
114	Additional value of volumetric and texture analysis on FDG PET assessment in paediatric Hodgkin lymphoma: an Italian multicentric study protocol. <i>BMJ Open</i> , 2021, 11, e041252.	1.9	5
115	Alveolar Rhabdomyosarcoma With Neuroendocrine Differentiation Detected by Ga-68 DOTA-NOC PET/CT. <i>Clinical Nuclear Medicine</i> , 2011, 36, 915-918.	1.3	4
116	Standardization of administered activities in paediatric nuclear medicine: the EANM perspective. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2275-2278.	6.4	4
117	In-vivo imaging of methionine metabolism in patients with suspected malignant pleural mesothelioma. <i>Nuclear Medicine Communications</i> , 2019, 40, 1179-1186.	1.1	4
118	Tumor metabolism and prognostic role of EZH2 in non-small cell lung cancer. <i>Translational Cancer Research</i> , 2017, 6, S982-S988.	1.0	4
119	Non-small cell lung carcinoma: understanding cancer microenvironment to drive immunotherapy and patients' selection. <i>Translational Cancer Research</i> , 2018, 7, S568-S572.	1.0	4
120	Does a 6-point scale approach to post-treatment 18F-FDG PET-CT allow to improve response assessment in head and neck squamous cell carcinoma? A multicenter study. <i>European Journal of Hybrid Imaging</i> , 2020, 4, 8.	1.5	4
121	Preliminary data on circulating tumor cells in metastatic NSCLC patients candidate to immunotherapy. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 9, 282-295.	1.0	4
122	Imaging with 11Carbon labelled PET tracers. <i>Nuclear Medicine Communications</i> , 2010, 31, 613-616.	1.1	3
123	"The simplest explanation is usually the correct one" Can Occam's razor be applied for diffuse astrocytoma and paradoxical amino acid metabolism?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1411-1412.	6.4	3
124	Cost-effectiveness of second-line diagnostic investigations in patients included in the DANTE trial. <i>Nuclear Medicine Communications</i> , 2019, 40, 508-516.	1.1	3
125	The role of 11C-methionine PET in patients with negative diffusion-weighted magnetic resonance imaging: correlation with histology and molecular biomarkers in operated gliomas. <i>Nuclear Medicine Communications</i> , 2020, 41, 696-705.	1.1	3
126	Metabolic Switch in Hepatocellular Carcinoma Patients Treated with Sorafenib: a Proof-of-Concept Trial. <i>Molecular Imaging and Biology</i> , 2020, 22, 1446-1454.	2.6	3

#	ARTICLE	IF	CITATIONS
127	Prognostic Value of Metabolic Imaging Data of 11C-choline PET/CT in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 472.	3.7	3
128	C-Methionine PET/CT in Central Nervous System Tumours: A Review. <i>Current Radiopharmaceuticals</i> , 2009, 2, 160-164.	0.8	3
129	Re: Stefano Fanti, Alberto Briganti, Louise Emmett, et al. EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy. <i>Eur Urol Oncol</i> . 2022;5:530â€“6. <i>European Urology Oncology</i> . 2022. 5. 601-602.	5.4	3
130	131I-MIBG Therapy of Malignant Neuroblastoma and Pheochromocytoma. , 2019, , 65-83.		2
131	Prostate cancer imaging and therapeutic alternatives with highly specific molecular â€˜probesâ€™. <i>BJU International</i> , 2019, 124, 188-189.	2.5	2
132	Mismatched Imaging Findings of Prostate Cancer Diagnosis: 68Ga-PSMA PET/CT vs mpMRI. <i>Nuclear Medicine and Molecular Imaging</i> , 2021, 55, 199-202.	1.0	2
133	[11C]-choline PET/CT in imaging locally advanced prostate cancer. <i>Nuclear Medicine Review</i> , 2011, 14, 118-119.	0.5	2
134	Interpretation of 2-[18F]FDG PET/CT in Hodgkin lymphoma patients treated with immune checkpoint inhibitors. <i>European Radiology</i> , 2022, , 1.	4.5	2
135	Malignant pleural effusion (MPE) characterized with 11C-Methionine PET/CT before and after talc pleurodesis: interim evaluation of a prospective clinical trial. <i>Annals of Oncology</i> , 2016, 27, vi525.	1.2	1
136	Reply: Diagnosis of Hyperprogressive Disease in Patients Treated with Checkpoint Inhibitors Using 18F-FDG PET/CT. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1405.2-1405.	5.0	1
137	Re: Michael S. Hofman, Nathan Lawrentschuk, Roslyn J. Francis, et al. Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Prostate Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multi-centre Study. <i>Lancet</i> 2020;395:1208â€“16. <i>European Urology</i> . 2020. 78. e131-e132.	1.9	1
138	Cancer management in the era of immunotherapy: much more than meets the eye. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 141-142.	0.7	1
139	Imaging struma ovarii by means of 124I-Na PET/CT. <i>Nuclear Medicine Review</i> , 2013, 16, 95-96.	0.5	1
140	How I faced my prostate cancer: a molecular biologistâ€™s perspective. <i>Npj Precision Oncology</i> , 2021, 5, 88.	5.4	1
141	Molecular imaging and targeted therapies in oncology: New concepts in treatment response assessment. A collection of cases. <i>International Journal of Oncology</i> , 1992, , .	3.3	1
142	11C-Methionine uptake in secondary brain epilepsy. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2014, 33, 234-236.	0.2	0
143	Positron emission tomography in pediatric and adult sarcoma. <i>Clinical and Translational Imaging</i> , 2015, 3, 83-93.	2.1	0
144	The diffusion-weighted imaging and 11-C-methionine positron emission tomography depiction of an endodermal cyst at the cervico-medullary junction. <i>British Journal of Neurosurgery</i> , 2015, 29, 739-741.	0.8	0

#	ARTICLE	IF	CITATIONS
145	Malignant pleural effusion (MPE) characterized with 11C-Methionine PET/CT before and after talc pleurodesis: interim evaluation of a prospective clinical trial. <i>Annals of Oncology</i> , 2016, 27, iv9.	1.2	0
146	Correlation of metabolic information on 18F-FDG PET with the tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) candidate to upfront surgery. <i>Annals of Oncology</i> , 2016, 27, iv8.	1.2	0
147	Mo1576 PET/CT Standardized Uptake Value of 11C-choline as a Predictor of Long-Term Survival in Patients Operated for Hepatocellular Carcinoma: A Preliminary Report. <i>Gastroenterology</i> , 2016, 150, S1238.	1.3	0
148	MP77-03 TARGETED 11C-CHOLINE PET/CT/TRUS SOFTWARE FUSION-GUIDED PROSTATE BIOPSY HAS IN MEN WITH PERSISTENTLY ELEVATED PSA AFTER PREVIOUS NEGATIVE BIOPSY. <i>Journal of Urology</i> , 2017, 197, .	0.4	0
149	Imaging HCC treated with radioembolization: review of the literature and clinical examples of choline PET utility. <i>Clinical and Translational Imaging</i> , 2020, 8, 377-392.	2.1	0
150	Conventional Radiological Techniques and PET-CT in Treatment Response Evaluation in Immunotherapy Settings. , 2021, , 83-99.		0
151	A Score for Predicting Freedom from Progression of Children and Adolescents with Hodgkin Lymphoma. <i>Hemato</i> , 2021, 2, 264-280.	0.6	0
152	Carcinomatosis peritoneal y met�stasis ocultas en el c�ncer de pr�stata: [68Ga]PSMA vs. [11C]Colina. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2021, 40, 261-262.	0.0	0
153	Peritoneal carcinomatosis and occult metastasis in prostate cancer: [68Ga]PSMA vs [11C]Choline. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2021, 40, 261-262.	0.2	0
154	Re: Hendrik Van Poppel, Ren�e Hogenhout, Peter Albers, et al. Early Detection of Prostate Cancer in 2020 and Beyond: Facts and Recommendations for the European Union and the European Commission. <i>Eur Urol</i> 2021;79:327��9. <i>European Urology</i> , 2021, 80, e24-e27.	1.9	0
155	Nuclear Medicine Procedures in Neuroblastoma. , 2020, , 139-162.		0
156	Malignant Pleural Mesothelioma: 18F-FDG PET/CT for Response Assessment of Malignant Pleural Mesothelioma Following Immunotherapy. , 2020, , 43-53.		0
157	Hematologic Malignancies: PET/CT for Response Assessment of Hematologic Malignancies Following Immunotherapy. , 2020, , 81-90.		0
158	Response Assessment and Follow-Up by Imaging in Breast Tumors. <i>Medical Radiology</i> , 2020, , 451-474.	0.1	0
159	Advances in Lung Cancer Imaging and Therapy. <i>Cancers</i> , 2022, 14, 58.	3.7	0
160	Multimodality imaging of ectopic focus in Graves' Disease. <i>Nuclear Medicine Review</i> , 2020, 23, 45-46.	0.5	0
161	Meditating on Cancer Management at the Time of Immunotherapy. <i>Journal of Clinical Medicine</i> , 2022, 11, 3025.	2.4	0